Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$18.72 USD

18.72
1,681,403

-0.54 (-2.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $18.72 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut

by Zacks Equity Research

Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.

Zacks Equity Research

Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut

by Zacks Equity Research

Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.

Zacks Equity Research

Wall Street Analysts See a 27% Upside in AMN Healthcare (AMN): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 26.8% upside potential for AMN Healthcare (AMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.

Zacks Equity Research

Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Zacks Equity Research

AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

Zacks Equity Research

AMN Healthcare Services (AMN) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 10.30% and 3.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 2.39% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.

Zacks Equity Research

Pfizer (PFE) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 21.09% and 7.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AMN or DOCS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Zacks Equity Research

Zacks.com featured highlights include Publicis Groupe S.A., Jabil, AMN Healthcare Services and A-Mark Precious Metals

by Zacks Equity Research

Publicis Groupe S.A., Jabil, AMN Healthcare Services and A-Mark Precious Metals are part of Zacks Screen of the Week article.

Zacks Equity Research

Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.

Moumita C. Chattopadhyay headshot

Look Beyond Profit, Pick These 4 Stocks With Rising Cash Flows

by Moumita C. Chattopadhyay

Cash is the most indispensable factor for any company. It holds the key to its existence, development and success. PUBGY, JBL, AMN and AMRK are worth buying, given their rising cash flow.

Zacks Equity Research

Elevance Health, Inc. (ELV) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's How Much a $1000 Investment in AMN Healthcare Services Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

AMN Healthcare (AMN) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

AMN Healthcare (AMN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $120.04 in the latest trading session, marking a +1.59% move from the prior day.

Zacks Equity Research

Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints

by Zacks Equity Research

Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.

Zacks Equity Research

Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Abiomed's (ABMD) Latest Impella Offering Approved by the FDA

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.

Zacks Equity Research

Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Combat Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.

Zacks Equity Research

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

Zacks Equity Research

Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

by Zacks Equity Research

Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.